AI Generated
Jul 2, 2026, 10:29
Nisar Ahmed: The Evolution of Anticoagulation Therapy
Nisar Ahmed, Pharmacist at Zubair Pharmacy, shared a post on LinkedIn:
“70 years of warfarin vs the new generation.
Here’s why anticoagulation has changed forever.
Warfarin — blocks vitamin K clotting factors, needs constant INR monitoring, dozens of food and drug interactions.
Still irreplaceable for mechanical heart valves.
Apixaban (Eliquis) — directly inhibits Factor Xa, predictable, no monitoring, fewer interactions.
The landmark ARISTOTLE trial: 21% less stroke, 31% less major bleeding, 11% lower mortality vs warfarin in AF.
- Mechanical heart valve? Stick with warfarin – DOACs are contraindicated.
- Non-valvular AF or VTE? Apixaban is now the standard of care.
- Full breakdown in the infographic . “
Stay updated with Hemostasis Today.
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada
-
Aug 24, 2026, 16:52Davide Capodanno: 10 Trials to Watch at the ESC Hot Lines
-
Aug 24, 2026, 16:48Mohd Ashhad: The Science Behind a Safe Transfusion
-
Aug 24, 2026, 16:38PCSK9i Is a Powerful Lipid-Lowering Strategy – But Is It Also Anti-Inflammatory?- JACC Journals
-
Aug 24, 2026, 16:36Alejandro González Veliz։ Does ACC/AHA Lesion Complexity Still Matter?
-
Aug 24, 2026, 16:21Kamlesh Darji: Paraneoplastic Syndromes – Tumor with or without Mediator
-
Aug 24, 2026, 15:15Jim Hoffman: Could Targeting NETosis Reduce Long-Term Risk After STEMI?
-
Aug 24, 2026, 14:58Danny Hsu: Rethinking Bleeding Risk in Patients on Anticoagulation
-
Aug 24, 2026, 14:18The Way to a Safer Workplace for People With Bleeding Disorders – EHC